• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

决策分析模型在组织创新决策中的应用:以助听器供应中的共同照护为例。

Decision-analytic modeling to assist decision making in organizational innovation: the case of shared care in hearing aid provision.

机构信息

Maastro Clinic, PO Box 5800, 6202 AZ Maastricht, The Netherlands.

出版信息

Health Serv Res. 2008 Oct;43(5 Pt 1):1662-73. doi: 10.1111/j.1475-6773.2008.00872.x. Epub 2008 Jun 3.

DOI:10.1111/j.1475-6773.2008.00872.x
PMID:18522663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2653881/
Abstract

OBJECTIVE

To illustrate the use of decision-analytic modeling to assist decision making in organizational innovations.

STUDY SETTING/DATA SOURCES: Regarding an organizational innovation (shared care in hearing aid provision) available evidence from different sources was synthesized.

STUDY DESIGN

A probabilistic Markov model was constructed.

DATA COLLECTION/EXTRACTION: We modeled the long-term cost-effectiveness of different organizational formats of shared care as opposed to the current organization. We assessed the expected value of perfect information (EVPI) for several groups of parameters in the model.

PRINCIPAL FINDINGS

The current organization had the highest probability of being cost-effective. Additional research is worthwhile, especially on access to care and safety (sensitivity to detect pathology).

CONCLUSIONS

Decision-analytic modeling in an early stage of organizational innovation is a valuable tool to facilitate evidence-based decision making.

摘要

目的

说明决策分析模型在组织创新决策中的应用。

研究环境/数据来源:综合了不同来源关于组织创新(助听器提供的共享护理)的可用证据。

研究设计

构建了概率马尔可夫模型。

数据收集/提取:我们对共享护理的不同组织形式与当前组织相比的长期成本效益进行建模。我们评估了模型中几组参数的完全信息预期价值 (EVPI)。

主要发现

当前组织具有最高的成本效益概率。特别是在获得护理和安全性方面(检测病理的敏感性),进一步的研究是值得的。

结论

在组织创新的早期阶段进行决策分析建模是促进循证决策的有价值工具。

相似文献

1
Decision-analytic modeling to assist decision making in organizational innovation: the case of shared care in hearing aid provision.决策分析模型在组织创新决策中的应用:以助听器供应中的共同照护为例。
Health Serv Res. 2008 Oct;43(5 Pt 1):1662-73. doi: 10.1111/j.1475-6773.2008.00872.x. Epub 2008 Jun 3.
2
The cost-effectiveness of hearing-aid fitting in the Netherlands.荷兰助听器验配的成本效益。
Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):297-304. doi: 10.1001/archotol.129.3.297.
3
Acceptability, benefit and costs of early screening for hearing disability: a study of potential screening tests and models.听力残疾早期筛查的可接受性、益处及成本:潜在筛查测试与模型研究
Health Technol Assess. 2007 Oct;11(42):1-294. doi: 10.3310/hta11420.
4
The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review.决策分析模型在外科创新评估中的应用:范围综述。
Value Health. 2021 Jun;24(6):884-900. doi: 10.1016/j.jval.2020.11.020. Epub 2021 Feb 25.
5
Patient preferences for direct hearing aid provision by a private dispenser. A discrete choice experiment.患者对私人助听器经销商直接提供助听器的偏好:一项离散选择实验。
Ear Hear. 2008 Aug;29(4):557-64. doi: 10.1097/AUD.0b013e3181734a19.
6
Difficult conversations: talking about cost in audiology consultations with older adults.艰难对话:在与老年人进行听力咨询时谈论费用问题。
Int J Audiol. 2017 Nov;56(11):854-861. doi: 10.1080/14992027.2017.1339128. Epub 2017 Jun 23.
7
Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.使用患者决策辅助工具指导骨质疏松症治疗的潜在成本效益。
Osteoporos Int. 2016 Sep;27(9):2697-2707. doi: 10.1007/s00198-016-3596-5. Epub 2016 May 7.
8
Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.助听器对老年听力障碍者的成本效益:一种概率方法。
Otol Neurotol. 2008 Sep;29(6):776-83. doi: 10.1097/MAO.0b013e31817e5d1b.
9
Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.用于成本效益分析的生存概率估计:多状态建模生存分析方法与分区生存及马尔可夫决策分析建模的比较
Med Decis Making. 2017 May;37(4):427-439. doi: 10.1177/0272989X16670617. Epub 2016 Oct 4.
10
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.多少证据才算足够?——运用系统决策分析和信息价值分析来确定是否需要更多证据。
Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575-84. doi: 10.1016/j.zefq.2013.10.020. Epub 2013 Nov 12.

引用本文的文献

1
Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression.深部脑刺激与常规治疗治疗抵抗性抑郁症的成本效益和阈值分析。
Transl Psychiatry. 2024 Jun 7;14(1):243. doi: 10.1038/s41398-024-02951-7.
2
A cost-minimisation analysis of performing point-of-care ultrasonography on patients with vaginal bleeding in early pregnancy in general practice: a decision analytical model.在一般实践中对早孕阴道出血患者进行即时超声检查的成本最小化分析:决策分析模型。
BMC Health Serv Res. 2022 Jan 11;22(1):55. doi: 10.1186/s12913-022-07463-y.
3
Evidence gaps in economic analyses of hearing healthcare: A systematic review.听力保健经济分析中的证据缺口:一项系统综述。
EClinicalMedicine. 2021 May 8;35:100872. doi: 10.1016/j.eclinm.2021.100872. eCollection 2021 May.
4
MR-Guided Focused Ultrasound Versus Radiofrequency Capsulotomy for Treatment-Refractory Obsessive-Compulsive Disorder: A Cost-Effectiveness Threshold Analysis.磁共振引导聚焦超声与射频囊切开术治疗难治性强迫症:成本效益阈值分析
Front Neurosci. 2019 Feb 7;13:66. doi: 10.3389/fnins.2019.00066. eCollection 2019.
5
Reflections on improving hospital performance.关于提高医院绩效的思考
Health Serv Res. 2008 Oct;43(5 Pt 1):1457-63. doi: 10.1111/j.1475-6773.2008.00903.x.

本文引用的文献

1
The value of implementation and the value of information: combined and uneven development.实施的价值与信息的价值:融合与不均衡发展
Med Decis Making. 2008 Jan-Feb;28(1):21-32. doi: 10.1177/0272989X07308751.
2
The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies.临床实践中指南实施经济评估的方法学质量:实证研究的系统评价
Value Health. 2007 Jul-Aug;10(4):305-16. doi: 10.1111/j.1524-4733.2007.00175.x.
3
Potential barriers and facilitators for implementation of an integrated care pathway for hearing-impaired persons: an exploratory survey among patients and professionals.听力障碍者综合护理路径实施的潜在障碍与促进因素:一项针对患者和专业人员的探索性调查
BMC Health Serv Res. 2007 Apr 19;7:57. doi: 10.1186/1472-6963-7-57.
4
Economic evaluation and decision making in the UK.英国的经济评估与决策制定
Pharmacoeconomics. 2006;24(11):1133-42. doi: 10.2165/00019053-200624110-00009.
5
Recent developments in decision-analytic modelling for economic evaluation.用于经济评估的决策分析模型的最新进展。
Pharmacoeconomics. 2006;24(11):1043-53. doi: 10.2165/00019053-200624110-00002.
6
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.医疗保健评估中决策分析建模的良好实践原则:ISPOR良好研究实践——建模研究特别工作组报告
Value Health. 2003 Jan-Feb;6(1):9-17. doi: 10.1046/j.1524-4733.2003.00234.x.
7
A rational framework for decision making by the National Institute For Clinical Excellence (NICE).英国国家卫生与临床优化研究所(NICE)的决策合理框架。
Lancet. 2002 Aug 31;360(9334):711-5. doi: 10.1016/S0140-6736(02)09832-X.
8
Representing uncertainty: the role of cost-effectiveness acceptability curves.表示不确定性:成本效益可接受性曲线的作用。
Health Econ. 2001 Dec;10(8):779-87. doi: 10.1002/hec.635.
9
Better health care decisions: fulfilling the promise of health services research.更好的医疗保健决策:兑现卫生服务研究的承诺。
Health Serv Res. 2000 Apr;35(1 Pt 2):175-86.
10
Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.药物经济学研究指南。健康与医学成本效益小组的建议。健康与医学成本效益小组。
Pharmacoeconomics. 1997 Feb;11(2):159-68. doi: 10.2165/00019053-199711020-00005.